15.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Axogen Inc Aktie (AXGN) Neueste Nachrichten
Axogen Inc. stock trend outlook and recovery path2025 Fundamental Recap & AI Based Buy and Sell Signals - newser.com
Visual analytics tools that track Axogen Inc. performanceJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
Will Axogen Inc. stock deliver strong dividend growthJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Real time social sentiment graph for Axogen Inc.Trade Analysis Report & Reliable Entry Point Trade Alerts - newser.com
What’s next for Axogen Inc. stock price2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
Can Axogen Inc. stock continue upward trendMarket Sentiment Review & Weekly Consistent Profit Watchlists - newser.com
Predicting Axogen Inc. trend using moving averagesJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - newser.com
Will Axogen Inc. stock gain from government policies2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Volume spikes in Axogen Inc. stock – what they meanGap Up & Verified Stock Trade Ideas - newser.com
How risky is Axogen Inc. stock nowAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Order flow analysis tools used on Axogen Inc.2025 Biggest Moves & Short-Term Trading Alerts - newser.com
Axogen, Inc. (AXGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AxoGen (NASDAQ:AXGN) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Why Axogen Inc. is moving today2025 Market Outlook & Reliable Breakout Forecasts - newser.com
How sentiment analysis helps forecast Axogen Inc.Portfolio Update Report & Verified Momentum Watchlists - newser.com
Can Axogen Inc. stock weather global recessionJuly 2025 Decliners & Low Risk High Reward Ideas - newser.com
AxoGen's (AXGN) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Market reaction to Axogen Inc.’s recent newsQuarterly Growth Report & Detailed Earnings Play Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc.AXGN - WV News
Axogen, Inc. Experiences Evaluation Revision Amidst Shifting Market Dynamics and Performance Indicators - Markets Mojo
Insider Sell: Burke William P. Mr. Sells Shares of Axogen Inc (A - GuruFocus
William Mr. Burke Sells 736 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Axogen Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
William Mr. Burke Sells 14,571 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
AxoGen (NASDAQ:AXGN) Director Sells $137,236.20 in Stock - MarketBeat
Axogen Director William P. Burke Sells Over 32,000 Shares - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Axogen, Inc. (AXGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
How to recover losses in Axogen Inc. stockJuly 2025 Earnings & Reliable Momentum Entry Alerts - newser.com
Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - Sahm
A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe - Yahoo Finance
AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Combining price and volume data for Axogen Inc.Trend Reversal & Safe Investment Capital Preservation Plans - newser.com
HighMark Wealth Management LLC Has $1.06 Million Position in AxoGen, Inc. $AXGN - MarketBeat
Equities Analysts Issue Forecasts for AxoGen Q3 Earnings - MarketBeat
FDA Extends Review for AxoGen’s Avance Nerve Graft - MSN
Canaccord Genuity reiterates Buy rating on AxoGen stock, citing BLA approval potential - Investing.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):